CD8 Minibody Repeatability Study

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: therapystablecellmetastaticconcurrent
  Phrases that lowered it: participantsparticipantsingleinvestigatorpatients who
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Primary purpose: diagnostic (lowers risk) · Design
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 4 (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, urogenital: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer NCT06863233 · started 2025 · scored riskier than 68% of active trials completed
• ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors NCT03802123 · started 2018 · scored riskier than 66% of active trials completed
• Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours NCT05638334 · started 2022 · scored riskier than 29% of active trials terminated
• Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies NCT03746704 · started 2019 · scored riskier than 29% of active trials terminated
• Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors NCT04169321 · started 2020 · scored riskier than 44% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.